63 results about "Mechanical thrombectomy" patented technology

Disclosed herein are clot treatment systems including integrated / systemized mechanical thrombectomy devices and clot treatment devices, and associated devices and methods. In some embodiments, a method of removing clot material from a blood vessel of patient includes inserting a catheter to proximate the clot material within the blood vessel while radially constraining a clot treatment device and an embolic protection device within the catheter. The method can further include moving the catheter proximally to deploy the clot treatment device at least partially distal to clot material within the blood vessel, and then moving the catheter further proximally to deploy the embolic protection device at least partially proximal to the clot material.

Disclosed herein are clot treatment systems including integrated / systemized mechanical thrombectomy devices and clot treatment devices, and associated devices and methods. In some embodiments, a method of removing clot material from a blood vessel of patient includes inserting a catheter to proximate the clot material within the blood vessel while radially constraining a clot treatment device and an embolic protection device within the catheter. The method can further include moving the catheter proximally to deploy the clot treatment device at least partially distal to clot material within the blood vessel, and then moving the catheter further proximally to deploy the embolic protection device at least partially proximal to the clot material.

Disclosed herein are clot treatment systems including mechanical thrombectomy devices and clot treatment devices, and associated devices and methods. In some embodiments, a method of removing clot material from a blood vessel of patient includes inserting a catheter to proximate the clot material within the blood vessel while radially constraining a clot treatment device and an embolic protection device within the catheter. The method can further include moving the catheter proximally to deploy the clot treatment device at least partially distal to clot material within the blood vessel, and then moving the catheter further proximally to deploy the embolic protection device at least partially proximal to the clot material. The clot treatment device can include one or more relief features configured to release captured clot material if the force on the clot treatment device exceeds a threshold.

Disclosed herein are clot treatment systems including mechanical thrombectomy devices and clot treatment devices, and associated devices and methods. In some embodiments, a method of removing clot material from a blood vessel of patient includes inserting a catheter to proximate the clot material within the blood vessel while radially constraining a clot treatment device and an embolic protection device within the catheter. The method can further include moving the catheter proximally to deploy the clot treatment device at least partially distal to clot material within the blood vessel, and then moving the catheter further proximally to deploy the embolic protection device at least partially proximal to the clot material. The clot treatment device can include one or more relief features configured to release captured clot material if the force on the clot treatment device exceeds a threshold.

Disclosed herein are clot treatment systems including mechanical thrombectomy devices and clot treatment devices, and associated devices and methods. In some embodiments, a method of removing clot material from a blood vessel of patient includes inserting a catheter to proximate the clot material within the blood vessel while radially constraining a clot treatment device and an embolic protection device within the catheter. The method can further include moving the catheter proximally to deploy the clot treatment device at least partially distal to clot material within the blood vessel, and then moving the catheter further proximally to deploy the embolic protection device at least partially proximal to the clot material. The clot treatment device can include one or more relief features configured to release captured clot material if the force on the clot treatment device exceeds a threshold.

The invention relates to the treatment of ischemic stroke at risk of brain swelling using SUR1-TRPM4 channel inhibitors in combination with mechanical thrombectomy. In some embodiments, the methods include treating patients suffering from a large hemispheric infarction. In certain embodiments, patients have a lesion volume of less than 140 cm3 or less than 125 cm3 as measured by MRI DWI or CTP. The patient may have suffered a wake-up stroke. Some embodiments involve treating patients who also undergo decompressive therapy.

An improved mechanical thrombectomy system is described herein that uses artificial intelligence to acquire, extrude, segment, and / or aspirate more effectively blood clots regardless of the age, size (e.g., length, diameter, etc.), solidness, or location of the blood clots while lowering the bleeding risk during the operation. For example, the improved mechanical thrombectomy system described herein can include a catheter, one or more sensors coupled to the catheter, and a control unit coupled to the catheter and sensor(s) that uses artificial intelligence to acquire, extrude, segment, and / or aspirate clots.

The invention relates to a superelastic intravascular thrombus removing instrument, and belongs to the technical field of medical instruments. The near end of the bracket connecting pipe is fixed with the operating handle; the movable pipe is movably arranged on the outer side of the support connecting pipe in a sleeving mode; the thrombolysis net basket comprises a plurality of capillary tubes which have elasticity and are connected with the movable tube, and the capillary tubes are provided with dosing holes; the expansion and contraction control component is used for controlling expansion and expansion or contraction and closing of the thrombolysis net basket; and the dosing mechanism is communicated with the plurality of capillary tubes and is used for inputting thrombolysis liquid medicine into the capillary tubes. According to the application, the mesh basket mechanical thrombus extraction and thrombolysis design is combined, so that the vascular injury can be reduced, the treatment cycle of administration and thrombolysis is shortened, and the surgical burden of a patient can be relieved.

The present invention relates to the field of medical equipment, and provides a thrombus removal device, which comprises a conveying assembly and a thrombus removal bracket, wherein the conveying assembly comprises an end, an inner tube, an intermediate tube, an outer tube and a suction catheter, wherein the end is connected to one end of the inner tube, the intermediate tube is movably sleeved with the inner tube, the outer tube is movably sleeved with the intermediate tube, a drug spraying hole is provided on the tube wall of the outer tube, the outer tube is suitable for conveying thrombolytic drugs to be sprayed from the drug spraying hole, the suction catheter is movably sleeved with the outer tube, and the suction catheter is suitable for aspirating thrombus; one end of the thrombus removal bracket is connected to the end, and the other end is connected to one end of the intermediate tube adjacent to the end, the thrombus removal bracket is sleeved on the outside of the inner tube and the intermediate tube, and the thrombus removal bracket moves with the inner tube and the intermediate tube to be exposed outside the outer tube or received inside the outer tube. The present invention improves the thrombus removal effect and efficiency through a combination of thrombolysis and mechanical thrombus removal.

A mechanical thrombectomy apparatus is provided. The mechanical thrombectomy device may comprise a support wire, a thrombectomy device, and a plurality of radiopaque markers. The thrombectomy device connects to the support wire and may comprise an expandable frame. The radiopaque markers can be attached to the expandable frame.

The invention relates to the technical field of medicines, in particular to application of DP-b99 and a derivative thereof in preparation of a medicine for treating cerebral ischemia mechanical thrombus extraction reperfusion injury. On the basis of mechanical thrombus extraction and reperfusion of cerebral ischemia, DP-b99 is combined to reduce mechanical thrombus extraction and reperfusion injury of cerebral arterial thrombosis, so that the inflammation level of brain tissues can be reduced, the volume of cerebral infarction can be reduced, the injury of the brain tissues can be effectively reduced, and the treatment effect is remarkable.

The invention relates to the treatment of ischemic stroke at risk of brain swelling using SUR1-TRPM4 channel inhibitors in combination with mechanical thrombectomy. In some embodiments, the methods include treating patients suffering from a large hemispheric infarction. In certain embodiments, patients have a lesion volume of less than 140 cm3 or less than 125 cm3 as measured by MRI DWI or CTP. The patient may have suffered a wake-up stroke. Some embodiments involve treating patients who also undergo decompressive therapy.

The present invention is entitled "Thrombectomy and Stent Implantation System". The present invention provides a design capable of both mechanical thrombectomy and stent implantation for the treatment of occlusions in the cerebral vasculature, which provides a three-catheter setup. A first outer catheter has the largest diameter and can serve as a guide catheter, while also serving as a sheath for the other catheters. A second deployment catheter can be configured for aspiration of the occlusion and can include a proximal stepped or recessed segment at the distal tip that can act as a housing for a woven expandable stent. The outer diameter of the stepped segment can be lined with an inflation device having a woven stent disposed on its top. Inside the second deployment catheter is a microcatheter that can deliver a mechanical thrombectomy device to the target site to retrieve the occlusion in the vessel, after which the stent can be expanded and implanted in the vessel.

This invention provides an interventional guidewire device for measuring intravascular oxygen saturation, belonging to the field of interventional surgical medical device technology. The guidewire device includes a guidewire body, a first oxygen measurement unit, and a second oxygen measurement unit. The guidewire body has a filamentous structure with a distal end and a proximal end. The first oxygen measurement unit is positioned at a predetermined distance from the distal end of the guidewire body and is used to measure oxygenation data at the distal end of the thrombus. The second oxygen measurement unit is positioned proximal to the first oxygen measurement unit and spaced at a predetermined distance from it, and is used to measure oxygenation data at the proximal end of the thrombus. During operation, the distal end of the guidewire body passes through the thrombus, with the first oxygen measurement unit positioned at the distal end of the thrombus and the second oxygen measurement unit positioned at the proximal end of the thrombus to measure oxygenation data at both ends of the thrombus. This invention primarily addresses the technical problem in existing technologies where it is impossible to assess oxygenation levels at the proximal and posterior ends of the thrombus before mechanical thrombectomy.

The invention relates to a reliability analysis method based on a self-adaptive agent model and importance sampling, belongs to the technical field of interventional medical stents, solves the problem of low reliability analysis efficiency of medical stents in the prior art, and is used for reliability analysis of mechanical thrombectomy stents. Comprising the following steps: quantifying random parameter probability distribution of a mechanical thrombectomy stent, and initializing algorithm parameters; generating a random sample, and obtaining a training sample set and a candidate sample set; constructing and training a Kriging agent model of the finite element model of the mechanical thrombectomy stent, and establishing an updated hypersphere; carrying out convergence judgment on the updated hypersphere radius; performing cross validation on the precision of the trained Kriging agent model by using a leave-one-out method; calculating a failure probability; and calculating a failure probability variable coefficient and carrying out convergence judgment, and when a convergence ending program is judged, applying the failure probability to safety evaluation and optimization design of the mechanical thrombectomy stent, otherwise, expanding the size of the candidate sample set and returning to regenerate a random sample.

A mechanical thrombectomy device, and methods of manufacturing and using the mechanical thrombectomy device, are described. The mechanical thrombectomy device includes a support wire and a clot arrestor. The clot arrestor has an expandable frame that includes an interior wall defining a lumen. The support wire is coupled to a proximal end of the clot arrestor and extends through the lumen along the interior wall. Other embodiments are also described and claimed.

Disclosed herein are clot treatment systems including mechanical thrombectomy devices and clot treatment devices, and associated devices and methods. In some embodiments, a method of removing clot material from a blood vessel of a patient includes inserting a catheter to proximate the clot material within the blood vessel while radially constraining a clot treatment device and an embolic protection device within the catheter. The clot treatment device can include a balloon catheter including an inflation port positioned on a proximal end of the balloon catheter and fluidly connected to a balloon on a distal end thereof. The balloon catheter includes an inflation control device fluidly connected to the inflation port, wherein the inflation control device is configured to reduce pressure within the balloon during inflation of the balloon.

A vascular therapy device (10) includes a retrieval device (12) configured to deploy an associated self-expanding stent (2) in a clot and including a retrieval line (14) attached to the associated self-expanding stent. At least one electronic processor (20) is programmed to: receive a time sequence of images (35) of the associated self-expanding stent acquired during a thrombectomy procedure in which the self-expanding stent is deployed in a clot; perform image analysis on the images of the time sequence of images to determine a geometric change of the associated self-expanding stent deployed in the clot; identify an event occurring in the thrombectomy procedure based on the geometric change of the associated self-expanding stent deployed in the clot; and respond to the identification of the event by: outputting an indication (36) of the event; and / or controlling a robot (16) to perform an action in response to the event.

The invention relates to the treatment of ischemic stroke at risk of brain swelling using SUR1-TRPM4 channel inhibitors. In some embodiments, the SUR1-TRPM4 channel inhibitor is used in combination with mechanical thrombectomy. In some embodiments, the methods include treating patients suffering from a large hemispheric infarction. In certain embodiments, patients have a baseline NIHSS of ≤ 20. In certain embodiments, patients have a lesion volume of less than 140 cm3 or less than 125 cm3 as measured by MRI DWI or CTP. The patient may have suffered a wake-up stroke. Some embodiments involve treating patients who also undergo treatment with a thrombolytic agent and / or decompressive therapy.

A mechanical thrombectomy device includes several clot arrestors mounted on a support wire. The clot arrestors have rings of expandable frame cells. The frame cell rings include an open frame cell ring, having a gap between adjacent frame cells in the ring, and a closed frame cell ring, having no gap between adjacent frame cells. The gap allows clots to enter the clot arrestor for retrieval from a target anatomy. Other embodiments are also described and claimed.

To provide the treatment of ischemic stroke at risk of brain swelling using SUR1-TRPM4 channel inhibitors in combination with mechanical thrombectomy.SOLUTION: In some embodiments, the methods include treating patients suffering from a large hemispheric infarction. In certain embodiments, the patients have a lesion volume of less than 140 cm3 or less than 125 cm3 as measured by MRI DWI or CTP. The patient may have suffered a wake-up stroke. Some embodiments involve treating patients who also undergo decompressive therapy.SELECTED DRAWING: None

The present invention is entitled "Improved Visibility of Mechanical Thrombectomy Devices During Diagnostic Imaging." The present invention provides a stretchable mechanical device for use during a thrombectomy medical procedure that has enhanced visibility during imaging. Furthermore, the configuration of the eyelets and / or struts optimizes retention of markers in the eyelets during the medical procedure and does not increase the overall profile of the struts.

The utility model discloses a negative pressure suction device for mechanical thrombectomy, which comprises an injector, a sealing cap, a three-way joint, a negative pressure hose and a plurality of one-way valves, the sealing cap is mounted at the tail of an empty cylinder on the injector and is in sliding sealing fit with a piston shaft, and the empty cylinder forms two variable pumping and drainage cavities through a piston and the sealing cap. The two variable pumping drainage cavities are communicated with first connectors of the two three-way connectors respectively, one negative pressure hose is communicated with second connectors of the two three-way connectors respectively, the other negative pressure hose is communicated with third connectors of the two three-way connectors respectively, and the one-way valves are installed between the negative pressure hoses and liquid outlets of the three-way connectors. The flow directions of every two adjacent one-way valves are opposite. According to the negative pressure suction device, reciprocating type double-stroke suction work can be formed by means of the injector, the negative pressure soft (guide) pipe and the like, suction work is completed twice between pulling and pushing of the injector, compared with an existing negative pressure suction device, the working efficiency is doubled, efficiency is high, existing materials are easy to obtain, and assembling is easy.

Improved systems including rBGCs improved by means of stiffness; working zones and optimized transition zones can traverse the aortic arch into the common carotid and vertebral arteries from a radial approach including navigation of tortuous and individuated anatomical challenges. Mechanical Thrombectomy improved by balloon occlusion prevents thrombus showers and follows 10 years of interventional cardiology and diagnostic use of improved radial approach (TRA) with better systems, making trans-femoral (TFA)less safe and effective than this revised treatment paradigm, unexpectedly better than literature predicted in early parts of the decade. Likewise, carotid stenting may be performed during these intracranial arterial occlusion procedures without swapping out guide catheters as required by the prior art.

A mechanical thrombectomy device includes several clot arrestors mounted on a support wire. The clot arrestors have rings of expandable frame cells. The frame cell rings include an open frame cell ring, having a gap between adjacent frame cells in the ring, and a closed frame cell ring, having no gap between adjacent frame cells. The gap allows clots to enter the clot arrestor for retrieval from a target anatomy. Other embodiments are also described and claimed.

Mechanical thrombectomy apparatuses, and particularly knitted rolling tube mechanical thrombectomy apparatuses configured to have improved tracking for delivery through tortious vessels are described herein. Also described herein are methods of removing clots using a mechanical thrombectomy apparatuses in which the clot is larger than the tractor portion of the mechanical thrombectomy apparatus.

The invention relates to the treatment of ischemic stroke at risk of brain swelling using SUR1-TRPM4 channel inhibitors. In some embodiments, the SUR1-TRPM4 channel inhibitor is used in combination with mechanical thrombectomy. In some embodiments, the methods include treating patients suffering from a large hemispheric infarction. In certain embodiments, patients have a baseline NIHSS of ≤ 20. In certain embodiments, patients have a lesion volume of less than 300 cm3, less than 140 cm3, or less than 125 cm3 as measured by MRI DWI or CTP. In certain embodiments, patients have a lesion volume expanding at a rate or < 25 mL / h. The patient may have suffered a wake-up stroke. Some embodiments involve treating patients who also undergo treatment with a thrombolytic agent and / or decompressive therapy.

This invention discloses a method and system for predicting the risk of malignant cerebral edema after mechanical thrombectomy in ischemic stroke, aiming to address the pain points of existing prediction tools, such as insufficient accuracy, lack of clinical interpretability, and difficulty in directly supporting decision-making. The core solution involves: stably extracting key predictive variables from multi-source clinical and laboratory data through a multi-algorithm consensus feature selection mechanism (LASSO, Boruta algorithm); employing eight machine learning algorithms to select the best high-performance prediction model, and using repeated cross-validation and grid search for robust optimization; innovatively and deeply integrating the SHAP interpretability framework to achieve global, local, and individualized interpretation of the model predictions; and finally deploying it as an integrated clinical decision support system, outputting a visual report that combines risk probability, risk classification, and decision-making basis. This method significantly improves the early risk identification capability of malignant cerebral edema, and the model exhibits excellent discrimination and calibration.